- Published at
- by manilatimes.net
neutral
neutral
News for Vaxart, Inc. (VXRT)
- Published at
- by zerohedge.com
positivepositiveRFK Jr Pauses Multi-Million Dollar Contract To Develop New COVID-19 Vaccine
ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero- Published at
- by manilatimes.net
mixedmixed- Published at
- by investing.com
neutralneutralVaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial By Investing.com
Vaxart Announces Favorable DSMB Review of Sentinel Cohort from COVID-19 Phase 2b Clinical Trial- Published at
- by finance.yahoo.com
positivepositiveVaxart project agreement change ups funding for oral COVID vaccine candidate
In a regulatory filing, Vaxart (VXRT) stated: “As previously disclosed on June 13, 2024, Vaxart, Inc. entered into an agreement with Advanced Technology International, the Consortium Management Firm of the Rapid Response Partnership Vehicle funded by the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services. Pursuant to the Project Agreement, the Company receives funding for a Phase 2b comparative study evaluating the Company’s oral pill XBB C- Published at
- by gurufocus.com
neutralneutralVaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. ( VXRT) today announced completion of enrollment of the sentinel cohort of a Phase- Published at
- by manilatimes.net
neutralneutral- Published at
- by seekingalpha.com
positivepositiveVaxart, Inc. (VXRT) Q3 2024 Earnings Call Transcript
Vaxart, Inc. (NASDAQ:VXRT) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ETCompany ParticipantsEdward Berg - Senior Vice President and General...- Published at
- by zacks.com
positivepositiveVAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates
VAXART (VXRT) delivered earnings and revenue surprises of 40% and 70.69%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by seekingalpha.com
neutralneutralEarnings Snapshot: Vaxart beats Q3 estimates; records R&D expenses of $15.1M (NASDAQ:VXRT)
Learn how to navigate the complex world of personal finance with expert tips and advice from our financial writer.- Published at
- by manilatimes.net
neutralneutral- Published at
- by seekingalpha.com
neutralneutralVaxart GAAP EPS of -$0.06 beats by $0.04, revenue of $4.93M beats by $3.43M (NASDAQ:VXRT)
Vaxart (VXRT) reports Q3 financial results with revenue of $4.93M, beating expectations.- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
positivepositiveVaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances
Revenue: $6.4 million for Q2 2024, compared to $1.4 million in Q2 2023.Cash, Cash Equivalents, and Investments: $62.6 million at the end of Q2 2024.Additional- Published at
- by investing.com
positivepositiveVaxart appoints Steven Lo as new President and CEO By Investing.com
Vaxart appoints Steven Lo as new President and CEO- Published at
- by benzinga.com
mixedmixed- Published at
- by globenewswire.com
mixedmixedNasal Vaccines Market Anticipated to Reach US$ 742.6 Million, Globally, by 2030 at 8.6% CAGR: Coherent Market Insights (CMI)
Nasal vaccines have emerged as a significant advancement in the field of vaccination, providing enhanced protection for both the vaccinated individuals and...- Published at
- by globenewswire.com
mixedmixedInfluenza Vaccine Market to Surpass 12.37 Billion by 2030 Drives Due to Growing Prevalence of Influenza Disease
SkyQuest projects that the influenza vaccine market will attain a USD 12.37 billion value by 2030, with a CAGR of 6.83% over the forecast period...- Published at
- by benzinga.com
mixedmixedCrude Oil Rises Over 1%; United Natural Foods Posts Downbeat Results - Farmer Bros (NASDAQ:FARM), Couchbase (NASDAQ:BASE)
U.S. stocks traded mixed toward the end of trading, with Dow Jones gaining around 100 points on Wednesday. The Dow traded up 0.30% to 33,672.74 while the NASDAQ fell 1.11% to 13,129.19. The S&P 500, also fell, dropping, 0.33% to 4,269.84.- Published at
- by benzinga.com
mixedmixedNasdaq Drops Over 100 Points; Campbell Soup Earnings Beat Estimates - Campbell Soup (NYSE:CPB), Couchbase (NASDAQ:BASE)
U.S. stocks traded mixed midway through trading, with Nasdaq Composite dropping over 100 points on Wednesday. The Dow traded up 0.20% to 33,639.18 while the NASDAQ fell 0.90% to 13,156.82. The S&P 500, also fell, dropping, 0.26% to 4,272.83.